Epigenetics Market Statistics, Trends & Growth Report

Global Epigenetics Market Size, Forecast, and Trend Highlights Over 2023 – 2035

Epigenetics Market size is estimated to reach ~USD 5 Billion by the end of 2035 by growing at a CAGR of ~17% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of epigenetics was ~USD 2 Billion. The growth of the market can be attributed to the rising incidence of cardiovascular diseases (CVDs) and the growing demand for personalized medicines. The World Health Organization estimates that 17.9 million people die each year from cardiovascular diseases (CVDs). According to the Centers for Disease Control and Prevention (CDC), people in the United States die of cardiovascular disease every 34 seconds. There were 697,000 deaths attributed to heart disease in the United States in 2020. As CVDs become more common, there is an increasing need for precision medicine solutions to identify and treat risk factors early on. Epigenetic testing is becoming increasingly popular as a tool to detect and identify at-risk individuals and to develop treatments tailored to the individual's unique genetic characteristics.

In addition to these, factors that are believed to fuel the market growth of epigenetics include increasing public awareness regarding the benefits of epigenetic tests, and a rise in the incidence of genetic conditions. Every year, approximately 1 in 200,000 people in the United States are diagnosed with syndrome A. There were an estimated 15,000 cases of syndrome B diagnosed worldwide in 2020. An increase in the number of people with genetic conditions has led to an increased demand for epigenetics services, such as DNA sequencing, epigenetic therapy, and genetic testing. These services allow for the diagnosis and treatment of genetic disorders. Furthermore, the emergence of new epigenetics technologies, such as ChIP-Seq, RNA-Seq, and ATAC-Seq, is also contributing to the growth of the market.

Global Epigenetics Market: Growth Drivers and Challenges

Growth Drivers

Rapidly Expanding Geriatric Population- The World Health Organization predicts a rapid growth in the global population consisting of people aged 65 and above from one billion in 2019 to about 1.4 billion by 2030, and to 2.1 billion by 2050, rather than a modest growth in population in 2019. Developing countries account for the majority of this growth. As the elderly population continues to grow, so does the need for therapies that can address age-related diseases such as cancer, neurodegenerative diseases, and cardiovascular diseases. Epigenetics has the potential to develop new therapies that can target these age-related diseases, thus driving the growth of the epigenetics industry.
Increasing Expenditure on Healthcare Research and Development Globally - For instance, in December 2021, the World Health Organization reported that gross domestic research and development expenditures on health (health GERD) in high-income countries were 0.21% of gross domestic product (GDP) and in the upper middle and low-income countries were 0.02% of gross domestic product (GDP). Governments and private organizations are increasingly spending on healthcare research and development activities to uncover the potential of epigenetics in the diagnosis and treatment of various diseases. This is expected to drive the growth of the epigenetics market over the forecast period.
Growth In the Approval of New Drugs - A record number of 59 new drugs were approved in 2018 compared with a record number of 50 new drugs approved in 2010, a 60% increase over the previous decade. The approval of drugs by the FDA is an important catalyst for epigenetics market growth. As more drugs are approved, more discoveries that can be made in the field of epigenetics, leading to new treatments and therapies.
Huge Base of Infectious Diseases Patients- Epigenetics is the study of how genetic expression can be altered without changing the underlying DNA sequence. As the number of infectious disease patients increases, the need for more effective treatments and therapies increases, making epigenetics an attractive area of study. According to the CDC, the number of infections registered so far in 2019 consists of 9,916 tuberculosis cases, 58,376 salmonella cases, 34,945 Lyme disease cases, and 371 meningococcal disease cases.
Rising Government Initiatives in Epigenetics Research To Develop Innovative Treatments - IHEC (Global Human Epigenetic Modification Collaboration), NCI (National Cancer Institute), & NIH (National Institutes of Health) are government initiatives that aim to develop innovative epigenetic therapies. Also, U.S. national human genome research institute launched the Encyclopedia of DNA Elements (ENCODE) project to identify all DNA sequence functional elements.

Challenges

Insufficient application of epigenetics data in toxicology - Epigenetics data is still relatively new and there is a lack of knowledge among toxicology experts on how to interpret and apply the data. Additionally, the cost of epigenetics testing is often prohibitive, making it difficult for toxicology labs to invest in the technology.
High cost associated with epigenetics services
Lack of skilled professionals to interpret the results of epigenetics tests

Global Epigenetics Market Segmentation

The global epigenetics industry is segmented and analyzed for demand and supply by product into kits and reagents, enzymes, and instruments. Out of these, the kits and reagents segment is estimated to gain the largest market share of about ~43% in the year 2035. The growth of the segment can be attributed to the increased demand for kits and reagents owing to the growing demand for precision medicine, the rising number of research activities in the field of epigenetics, and the increasing prevalence of cancer among other diseases. It is estimated that more than 74,000 genetic testing products and 300 personalized medicines are available for people suffering from different types of cancers, genetic diseases, chronic conditions, and infectious diseases. Additionally, continuous technological advancements and increasing investments in the biotechnology sector are anticipated to further drive the growth of the segment.

The global epigenetics market is segmented and analyzed for demand and supply by technology into methylation, acetylation, phosphorylation, and others. Out of these, the methylation segment is estimated to gain a significant market share of about ~37% in the year 2035. The growth of the segment can be attributed to the rising demand for DNA methylation technology in the pharmaceutical and biotechnology industries, as it helps to study the effects of environmental and dietary factors on gene expression. Additionally, the development of next-generation sequencing technologies has enabled researchers to identify methylation sites on a large scale, thereby driving the growth of the segment. The advent of next-generation sequencing technologies has allowed for the rapid and accurate identification of methylation sites, which has enabled researchers to better understand the effects of environmental and dietary factors on gene expression.

Our in-depth analysis of the global epigenetics market includes the following segments:

By Product	Kits and Reagents Enzymes Instruments
By Application	Oncology Autoimmune Diseases Metabolic Diseases CNS/Pain Diseases Cardiovascular Diseases
By End User	Academic & Research Institutes Pharmaceutical & Biotechnology Companies Contract Research Organizations
By Technology	Methylation Acetylation Phosphorylation Others

Global Epigenetics Market Regional Synopsis

The market share of epigenetics in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~35% by the end of 2035. The growth of the market can be attributed primarily to the rapid development of healthcare infrastructure and the increasing prevalence of cancer in the population. According to the American Cancer Society, as of 2022, the number of new cancer cases in the United States was estimated to be 1.9 million, and the number of cancer deaths was calculated to be 609,360. The rising number of cancer cases has increased the demand for advanced treatment options, such as epigenetics, which can help identify and target individual cancer cells. Moreover, a significant amount of money is being invested in understanding the molecular basis of cancer in the United States, with the aim of developing cancer therapeutics. Additionally, the availability of sophisticated tools and technologies, the growing focus of government initiatives on the development of life sciences, and the presence of a large number of major players in the region are some of the other factors contributing to the growth of the epigenetics market in North America.

The Asia Pacific epigenetics market is estimated to be the second largest, registering a share of about ~27% by the end of 2035. The growth of the market can be attributed majorly to the increasing prevalence of lifestyle diseases and growing awareness among the population about epigenetics. With the rise in lifestyle diseases such as diabetes and obesity, there is an increased demand for personalized treatments that are tailored to each person's genetic makeup. This has led to an increased focus on epigenetics, which studies how gene expression can be modified without changing the underlying genetic code. Additionally, the rise in R&D investments, supportive government initiatives and policies, and the development of innovative products in the market are some of the other factors that are propelling the growth of the Asia Pacific epigenetics market.

Further, the epigenetics market in Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The growth of the market can be attributed majorly to technological advancements, such as the development of innovative products and services, and the increasing number of collaborations and partnerships between the industry players in the region. Recent technological advancements in the field of epigenetics, such as the development of new tools and techniques to study gene expression, have enabled the rapid development of a range of products and services. This has enabled the European epigenetics market to be competitive in a world market and to develop innovative products and services to meet customer needs. Additionally, the growing awareness about epigenetics among healthcare professionals and end-users is also expected to contribute to the growth of the market in Europe.

Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Global Epigenetics Market

Abcam PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Diagenode Inc.
Merck KGaA
Element Biosciences, Inc.
PacBio
Active Motiff
Illumina Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
EpiGentek Group Inc.

In The News

In partnership with Dovetail Genomics, the developer of a new and disruptive DNA sequencing platform, Element Biosciences Inc. A demonstration of Dovetail's proximity ligation-based library preparation solutions for next-generation sequencing will be conducted on the AVITI System of Element Biosciences.
A leading developer of high-quality, highly accurate sequencing solutions, PacBio, has introduced its Sequel IIe and Sequel II systems with a new capability to detect DNA methylation. These new systems have the ability to identify specific regions of the genome that have been altered by methylation, which is a type of chemical modification to DNA that can influence gene expression.

Global Economic Impact

Request Insights

Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Key Questions Answered in the Report

1) What are the major factors driving the growth of the epigenetics market?

Ans: Increasing prevalence of lifestyle-related chronic diseases such as cancer, diabetes, and cardiovascular diseases, and increasing research activities in the field of epigenetics are the major factors driving the market growth.

2) What would be the CAGR of epigenetics market over the forecast period?

Ans: The market size of epigenetics is anticipated to attain a CAGR of ~17% over the forecast period, i.e., 2023 – 2035.

3) What are the challenges affecting the epigenetics market growth?

Ans: High cost associated with epigenetics services and the lack of skilled professionals to interpret the results of epigenetics tests are estimated to be the growth hindering factors for the market expansion.

4) Which region will provide more business opportunities for growth of epigenetics market in future?

Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

5) Who are the major players dominating the epigenetics market?

Ans: The major players in the market are Abcam PLC, Diagenode Inc., Merck KGaA, Element Biosciences, Inc., PacBio, Active Motiff, Illumina Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., EpiGentek Group Inc., and others.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the epigenetics market?

Ans: The market is segmented by product, application, end user, technology and by region.

8) Which segment captures the largest market size in the product segment in the epigenetics market?

Ans: The kits and reagents segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Base Year	2022
Forecast Year	2023-2035
CAGR	~17%
Base Year Market Size (2022)	~ USD 2 Billion
Forecast Year Market Size (2035)	~ USD 5 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)